Skip to main content

Zelluna

Zelluna ASA is a Norwegian clinical-stage biopharmaceutical and immunotherapy enterprise specializing in the discovery, development, and commercialization of engineered T-cell receptor (TCR) therapies designed to treat solid tumor cancers. The company utilizes proprietary non-engineered and engineered TCR technology platforms to develop cellular immunotherapies that direct patient immune cells to recognize and destroy hard-to-treat cancerous tumors. Its core business operations encompass biopharmaceutical research, cellular immunotherapy engineering, clinical trial execution, and pharmaceutical product development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings, grants, and strategic research partnerships. Zelluna holds a pioneering market position in T-cell receptor immunotherapy and solid tumor oncology. The company is headquartered in Oslo, Norway, and operates as a specialized biotechnology enterprise.

3 of the funds FundTelligence covers report a position in Zelluna.

Legal name
Zelluna ASA
Sector
Health Care
Country
Norway
Funds holding it
3

Funds holding Zelluna

Loading...